Ifosfamide in testicular cancer.
P J Loehrer
Abstract
P J Loehrer
Abstract
Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40% to 50% of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40% to 50% of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.
Key concepts: Ifosfamide, Medicine, Testicular cancer, Cisplatin, Nitrogen mustard, Chemotherapy, Refractory (planetary science), Germ cell tumors